Cimicoxib for the Treatment of Major Depression (SECIM)

Summary

This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression. This clinical study is based on the assumption that adjunctive treatment of major depression with a COX-2 inhibitor may be beneficial.

Timeline

Start

2007-10

Primary completion

2010-02

Completion

2010-02

Drugs

Indications